Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Industry makes strides in melanoma

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Ipilimumab stimulates antitumor immunity by blocking CTLA4, a natural brake on T cells, and allowing their unimpeded 'costimulation'.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Garber, K. Industry makes strides in melanoma. Nat Biotechnol 28, 763–764 (2010). https://doi.org/10.1038/nbt0810-763

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0810-763

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer